ProCE Banner Activity

Incorporating Adjuvant Immunotherapy Into the Treatment of Patients With High-Risk HCC

Clinical Thought

Read expert responses to questions on the role of adjuvant immunotherapy in patients with high-risk HCC following resection or ablation.

Released: April 08, 2024

Expiration: April 07, 2025

Share

Faculty

Amit Singal

Amit Singal, MD, MS

Professor of Medicine
Medical Director of Liver Tumor Program
Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Disclosure

Primary Author

Amit Singal, MD, MS

Professor of Medicine
Medical Director of Liver Tumor Program
Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

Amit Singal, MD, MS: consultant/advisor/speaker: AstraZeneca, Bayer, Boston Scientific, Genentech, Glycotest, Eisai, Elevar, Exact Sciences, Exelixis, Fujifilm Medical Sciences, HistoSonics, Merck, Roche, Sirtex.

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mark Yarchoan, MD: consultant/advisor/speaker: AstraZeneca, Eisai, Exelixis, Genentech, Hepion, Lantheus, Replimune; researcher (paid to institution): Bristol-Myers Squibb, Genentech, Incyte; owner: Adventris.